Takeda Pharmaceutical Co Ltd

Takeda’s Phase 3 win for oral psoriasis drug zasocitinib offers a safe, effective, cost‑efficient option poised to reshape the competitive, reimbursement‑driven dermatology market.

Takeda’s 52‑week VERIFY study shows rusfertide safely reduces phlebotomy in polycythemia vera, offering durable efficacy and a strong commercial case for market access.

Takeda’s 52‑week rusfertide study shows 83 % hematocrit control and low thrombotic risk, while its multibillion‑dollar Innovent partnership targets next‑gen immuno‑oncology therapies.

Takeda’s shares edge toward a historic peak as investors eye its strong oncology, GI and CNS pipeline, with promising Phase‑III data and upcoming regulatory approvals driving confidence.

Takeda Pharmaceutical Co. Ltd. has formed a strategic alliance with Innovent Biologics to co-develop and commercialize several late-stage investigational agents, expanding its oncology portfolio and positioning the company to capture a larger share …

Takeda Pharmaceutical Co Ltd has announced significant progress in its cancer treatments, including reimbursement of its cancer drug FRUZAQLA in Quebec and advancements in γδ T cell cancer treatments.

Takeda Pharmaceutical’s cancer drug FRUZAQLA has been publicly reimbursed for treating metastatic colorectal cancer in Quebec, following positive recommendations from Canadian health agencies.

Takeda Pharmaceutical’s recent stock price surge may be a sign of strength, but its long-term success is uncertain and depends on the success of its research and development efforts.

Takeda Pharmaceutical Co Ltd’s stock price has moderately increased over the past year, with a market capitalization and high price-to-earnings ratio, but recent developments have had no direct impact on its stock price or operations.

Takeda Pharmaceutical has released its quarterly earnings report, highlighting its growth trajectory and market position, but also raising concerns about its valuation and debt levels.